Life Science Leadership Series: Anti-microbial Resistance

Life Science Leadership Series: Anti-microbial Resistance 20 May 2015 The Nucleus, Chesterford Research Park, Little Chesterford CB10 1XL

Programme 10.00

Registration

10.30 Welcome and introduction Tony Jones, Business Development Director, One Nucleus 10.40

Keynote Speaker 1 – An Overview of the Microbial Resistance Challenges and How to Meet Them Ian Morrissey, Director of New Business and Project Development for Europe, Middle East and Asia at IHMA Europe Sàrl

11.10 Keynote Speaker 2 – The Reality of Combating Infectious Diseases without the Right Tools Ed Cole, International Advisory Board Member, Massanga Hospital, Sierra Leone 11.40 Keynote Speaker 3 – A game changing new antibiotic? The Discovery of Teixobactin Vicky Steadman, Assoc. Dir. Discovery, Selcia Ltd 12.10 Fixing the Broken Business Model in Anti-infectives Rachel Armstrong, Partner, PWC 12.40

Closing remarks

12.45

Lunch and networking

14.00 Measurement accuracy in AMR Jim Huggett, LGC 14.25 The Role of Vaccines in Combating AMR Fiona Marston, Absynth Biologics 14.50 Reaching the Site of Action David Knowles, Procarta Biosystems 15.15 Pre-clinical vaccine target validation (title tbc) Neil Williams, CSO, KWS Biotest

15.40

Closing Remarks

15.45

Tea, coffee and networking

16.15

The Journey to New Antibiotics Richard Bax, TranScrip Partners

16.40

Application of Nanotechnology for Microbial Control Chris Wright, Centre for NanoHealth, University of Swansea

17.05

A New Approach to Rapid POC Diagnostics in Sepsis Nick Burroughs, BJS BioTechnologies Ltd

17.30

Keynote Speaker 4: Performing Clinical Trials in the Hot Zone?

Miles Carroll, Public Health England

17.55

Closing Remarks

18.00

Networking over drinks and canapes

19.00

Event closes

Speaker Profiles Rachel Armstrong Strategy Consultant, Life Sciences and Pharmaceutical Practice, PwC UK Rachel is currently a strategy consultant in the UK Pharmaceutical & Life Sciences practice in PwC. She is seconded to PwC from the UK Civil Service.

Rachel works with global pharmaceutical clients to provide advice and insight on a range of strategic issues. Her particular area of specialism is in innovative commercial models, which combine commercial returns and health outcomes often through risk-share arrangements, to benefit industry, governments and patients.

Before joining PwC Rachel spent almost a decade in the UK civil service, including holding senior policy advisory roles in the Department for Business and Department of Health. Rachel advised UK Government ministers on a range of social, health & economic policy issues.

Richard Bax, Senior Partner TranScip Partners Richard Bax has been at TranScrip Partners for 5 years and has been involved in a large range of activities such as preparation of development plans, MAA’s, company strategies spanning all stages of development as well as liaising with regulators, investors, learned societies and prescribers in the anti-infective area.

Richard sits on several companies advisory boards as well as participating and presenting at meetings of the EMA, MRC, IMI (Combacte-Magnet), EU commission, Wellcome Trust, British Society for Antimicrobial Chemotherapy, the Jim O’Neill review and others.

Richard has published over 100 articles on Clinical Trials, Antibiotic Drug Development and Use and the Pharmaceutical industry in peer reviewed journals and 8 book chapters.

Richard is currently an Honorary Visiting Senior Scientist in the department of clinical pharmacology at Kings College London.

Nick Burroughs, CEO BJS Biotechnologies Nick joined BJS Biotechnologies in 2010, bringing 25 years’ experience and business expertise in strategy, product development, and world class manufacturing.

He has held senior executive and director roles in UK listed companies across a wide spectrum of business sectors, including biotechnology, engineering and instrumentation. He has a background is in product design and is a physics graduate.

With a detailed sector knowledge in a number high technology industries including healthcare he has a history of creating high growth scenarios.

In his spare time he still plays rugby, but more slowly these days, and is restoring an Austin Healey 3000.

Ed Cole Chairman, International Board of Masanga Hospital, Sierra Leone Ed Cole is the MD and Founder of EDAC Intellectual Property Management Consulting services, and, since 2006, has been Chairman of the international Board of Masanga Hospital, Sierra Leone. This provides Executive Board leadership in a pan-European group comprising of physicians and business professionals operating a 100 bed hospital in Sierra Leone (Masanga Hospital www.masangahospital.org.) Led negotiation with the Government of Sierra Leone for rehabilitation and management of the Hospital, which currently provides maternity, paediatric, general health care and have strong education and sustainability business units. It runs a Technology and Health Sciences Training College and a pioneering surgical training program. Under its Masanga Mentor Ebola initiative, it is using advanced technology to transform training to combat the spread of Ebola http://www.telegraph.co.uk/news/ telegraphchristmasappeal/11308607/How-gaming-technology-could-stop-the-spread-ofEbola.html) Ed holds a PhD in chemistry, and with over 20 years’ experience in intellectual property (IP) management, technology transfer, patent assertion licensing, innovation scouting and business development in major multinational and SME businesses. (BTG, BT, Rovi).

Jim Huggett Principal Scientist, LGC Dr Huggett is the Principal Scientist for Nucleic Acid Research at LGC, a company that is also the UK’s designated National Measurement Institute for chemical and bioanalytical measurement.

He received his PhD at Cardiff University before working as a Senior Research Fellow at UCL investigating molecular diagnosis of infectious diseases in the developing world. At LGC he oversees molecular diagnostics and genomics research. Much of his interests are focussed on high accuracy molecular analysis as well as improving reproducibility of measurements like those performed in AMR analysis. This aims to increase the impact of both applied methods and pre-clinical research. Dr Huggett retains an honorary lectureship at UCL and is Managing Editor of the Journal of Biomolecular Detection and Quantification (http://www.journals. elsevier.com/biomolecular-detection-and-quantification).

Ian Morrissey Director, New Business and Project Development for Europe, Middle East and Asia, IHMA Europe Sàrl Since 1987, Ian has been actively engaged with the pharmaceutical industry to support the development of new antimicrobials, particularly pre-clinical and surveillance studies.

Ian obtained his Ph.D. from the School of Pharmacy, University of London (UK) in 1990 and Executive MBA from Imperial College Management School, University of London (UK) in 2001.

Between 1990 and 1995, he held Research Fellowships at the School of Pharmacy, at Daiichi Pharmaceutical Co Ltd. (Japan) and at the University of East London (UK). After this Ian was a Lecturer and then Senior Lecturer at the University of Hertfordshire (UK) until 1998 when he moved to GR Micro Ltd (Quotient Bioresearch Ltd.) before joining IHMA Europe in 2012.

Ian is a Fellow of the Royal Society of Medicine and an enthusiastic supporter of the British Society for Antimicrobial Chemotherapy (BSAC). He has held positions of General Secretary and Chairman of the Grants Committee at the BSAC as well as representing the BSAC on the Steering Committee for UK Standards for Microbiology Investigations. Ian is also an advisor to the Clinical Laboratory Standards Institute (CLSI) veterinary antimicrobial susceptibility standards subcommittee and is the sole or co-author of more than 300 publications/ presentations on antimicrobial action and resistance.

Vicky Steadman Associate Director, Selcia Vicky joined Selcia in 2008 as a senior scientist and was promoted less than a year later to group leader where she led key client discovery projects. She became Associate Director of Discovery in 2013. She has significant previous big pharma experience, having worked in senior scientific roles at GSK and Merck.

Her main areas of experience include anti-viral, anti-bacterial and anti-inflammatory macrolides, as well as Alzheimer’s disease targets.

Vicky has a BSc in chemistry from Imperial, a PhD from Cambridge and held a Royal Society Fulbright Postdoctoral Fellowship at the University of Pennsylvania. She is named on over 20 peer reviewed papers and patents.

Chris Wright Reader, Swansea University Chris Wright is Reader at the College of Engineering Swansea University. He received his BSc in Applied Biology from Cardiff University and completed his PhD at Swansea in Biochemical Engineering. He was awarded an EPSRC Fellowship in 2001 and established an internationally recognized group for the characterisation and control of microbial interactions.

He was Portfolio Director for Chemical Engineering and established Medical Engineering and Environmental Engineering degree courses. He is Director of the Multidisciplinary Nanotechnology Centre, and founding executive member of the Centre for NanoHealth. He has 100 international publications, 15 book chapters and is editor of 2 books within the area.

Delegate List First name Rachel Richard Pamela Nick Miles Iphigenie Sue Robert Ed Greer Bobby Gemma Jim Huw Tony Devarshi Yvonne David Robin Rebecca Fiona Ajay Inigo Ian Jonathan David Tony Mike Jacques Clare Daniel Tom Nadia Ed Vicky Claire

Surname Armstrong Bax Brown Burroughs Carroll Charatsi Charles Clay Cole Deal Deal Howe Huggett Jenkins Jones Kapadia Kennard Knowles Leach Lo Marston Mistry Montes Morrissey Powell Rainford Raynham Romanos SAMARUT Sansom Shaw Shepherd Shivji Siegwart Steadman Struthers-Semple

Ismael Joanne Neil Chris

Tejero Wayne Williams Wright

Company PricewaterhouseCoopers LLP TranScrip Partners Cantab Anti-Infectives Ltd BJS BIOTECHNOLOGIES Ltd Public Health England Public Health England Instinctif Partners ( Life Sciences) Highbury Regulatory Science Limited International Board of Masanga GRS GRS Instinctif Partners ( Life Sciences) LGC J A Kemp One Nucleus LGC Ltd CIMYM BioSciences Ltd Procarta Biosystems Ltd Eurofins CerepPanlabs University of East Anglia (UEA) Absynth Biologics Isogenica Ltd LGC IHMA Europe Sàrl Domainex Ltd Taylor Vinters Solicitors University of East London Crescendo Biologics ENS Lyon Dr Clare Sansom (freelance) Reddie & Grose LLP ENS Lyon One Nucleus LGC Selcia Limited Valevia UK Ltd. University of Leicester- Enterprise & Business Development Office Vernalis KWS BioTest Ltd University of Swansea-Centre for NanoHealth